PINK:IPSEY

Ipsen S.a Stock News

Healthcare > Drug Manufacturers - Specialty & Generic

Buy IPSEY

*Your capital is at risk

$46.50

+1.11 (+2.45%)

At Close: Jun 23, 2026

Ipsen Announces Publication of First Matching-Adjusted Indirect Comparison of Cabometyx® (cabozantinib) Versus regorafenib in Advanced Hepatocellular Carcinoma in Advances in Therapy

12:00am, Tuesday, 19'th May 2020

Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced that data from the matching-adjusted indirect comparison (MAIC) of Cabometyx® (cabo

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by